Transamination and Amino Group Transfer (PLP)

The discovery that organisms can interconvert amino acids by moving nitrogen between carbon skeletons was one of the pivotal insights of twentieth-century biochemistry. Before transamination was understood, nutritional science could not explain how the body synthesizes certain amino acids from dietary precursors, nor could clinicians interpret the enzyme assays that would become cornerstones of liver-function diagnostics. The identification of transamination as a general metabolic strategy, and of pyridoxal 5′-phosphate (PLP) as its obligatory coenzyme, resolved a central question in nitrogen metabolism: how does an organism redistribute amino groups efficiently without generating free ammonia at every step? The timeline below traces the key discoveries that built our modern understanding.

The central question that transamination answers is elegant in its simplicity: how does the cell move nitrogen from amino acids that are in excess to carbon skeletons that need an amino group, all without wasting energy or generating toxic free ammonia? The answer lies in a remarkably versatile coenzyme — PLP — and a family of enzymes, the aminotransferases, that have evolved to exploit PLP chemistry across hundreds of distinct reactions.

Transamination is governed by a small set of chemical and enzymatic principles that recur across essentially all aminotransferase-catalyzed reactions. Understanding these principles provides a framework for reasoning about nitrogen flow in any metabolic context, from liver gluconeogenesis to brain neurotransmitter recycling.

The diagram above captures the essence of the ping-pong mechanism. Notice that the enzyme never simultaneously binds both substrates; instead, it toggles between two stable states — the PLP form (aldehyde) and the PMP form (amine). The quinonoid intermediate, shown in pink, is the resonance-stabilized carbanion that sits at the mechanistic crossroads: abstraction of the α-proton from the external aldimine generates this species, and reprotonation at C-4′ of PLP converts it to the ketimine. The stereochemical outcome at the α-carbon of the product amino acid is controlled by which face of the quinonoid intermediate the enzyme-bound acid–base residue protonates.

Schiff-Base Chemistry — The Heart of PLP Catalysis

The catalytic power of PLP rests on its ability to form Schiff bases (imines) with amino acid substrates. In the resting enzyme, the aldehyde group of PLP condenses with the ε-amino group of a conserved active-site lysine residue to form an internal aldimine. When a substrate amino acid enters the active site, its α-amino group displaces the lysine in a transimination (transaldimination) reaction, yielding an external aldimine. This external aldimine is the branching point for all PLP-dependent reaction types — transamination, decarboxylation, racemization, and β/γ-elimination — depending on which bond to the α-carbon the enzyme labilizes.

Electron-Sink Mechanism

The protonated pyridinium nitrogen of PLP acts as a powerful electron sink. When the α-proton of the external aldimine is abstracted by the active-site base (the freed lysine ε-amino group), the resulting carbanion is stabilized by delocalization of the negative charge through the conjugated π system all the way to the positively charged ring nitrogen. This quinonoid intermediate is spectroscopically detectable (λ_max ≈ 490–500 nm, giving a yellow-to-orange color change) and represents the lowest-energy point on the reaction coordinate before reprotonation at C-4′ redirects the reaction toward the ketimine product. Dunathan's stereoelectronic hypothesis (1966) elegantly explains substrate specificity: the bond to be broken at the α-carbon must be oriented perpendicular to the plane of the PLP–imine conjugated system for optimal orbital overlap with the π system.

While the aminotransferase family includes hundreds of members across all domains of life, two enzymes dominate clinical and metabolic discussions in human biochemistry: aspartate aminotransferase (AST, also called GOT) and alanine aminotransferase (ALT, also called GPT). Both use α-ketoglutarate as the amino-group acceptor in their physiologically predominant directions, funneling nitrogen toward glutamate — the central nitrogen hub of amino acid metabolism. The table below summarizes the properties and metabolic contexts of these and other key aminotransferases.

The diagram illustrates a crucial design principle of nitrogen metabolism: rather than having each amino acid catabolized by a unique ammonia-releasing enzyme, the cell uses aminotransferases to converge nitrogen into a single collector molecule — glutamate. This strategy minimizes the number of enzymes needed to interface with the urea cycle and provides tight control over free ammonia levels, which is critical because free NH₄⁺ is neurotoxic at concentrations above approximately 50 µM in blood.

Let us walk through the complete transamination catalyzed by alanine aminotransferase (ALT), beginning with an excess of alanine produced by muscle during vigorous exercise and ending with the products that feed gluconeogenesis and nitrogen disposal in the liver. This is the biochemical basis of the glucose–alanine cycle (Cahill cycle).

Aminotransferases are among the most clinically relevant enzymes in laboratory medicine. Because AST and ALT are abundant in hepatocytes and are released into the bloodstream upon cell damage, their serum levels serve as sensitive markers of liver injury. However, the diagnostic utility of these enzymes extends well beyond simple detection of hepatocellular damage — the AST/ALT ratio (De Ritis ratio) provides differential diagnostic information. The table below compares the features and clinical roles of these two key enzymes.

Transamination does not exist in isolation — it is deeply integrated with several advanced metabolic and biochemical topics. Understanding how PLP-dependent amino group transfer connects to the urea cycle, the malate-aspartate shuttle, gluconeogenesis, and even neurotransmitter metabolism provides the broader systems-level perspective essential for upper-division biochemistry and medical biochemistry courses.

As you advance to studies of metabolic integration, inborn errors of metabolism, and pharmacology, you will encounter transamination repeatedly. For example, the drug vigabatrin is an irreversible inhibitor of GABA transaminase, used to treat epilepsy by elevating brain GABA levels. Understanding its mechanism requires exactly the PLP chemistry covered in this lesson — vigabatrin is a suicide substrate that forms a covalent adduct with PLP in the GABA-T active site, permanently inactivating the enzyme. This intersection of coenzyme mechanism and pharmacological design illustrates the translational power of fundamental biochemistry.